 This is a multi-center, proof of concept phase 0 study to assess the suppression of p-AKT in VS and meningiomas by AR-42 in adult patients undergoing NF2-tumor resection. AR-42 will be administered three times per week beginning 3 weeks prior to surgery. A total of ten doses, - 1 dose at 40 mgdose, will be self-administered orally by study participants at approximately the same time every day - 1 hour, preferably in the evening 3 times per week for 3 weeks pre-operatively, with the last dose taken the night before surgery. Patients will be evaluated within the context of their standard post-operative follow up which includes within 2 days of surgery and again at 2 weeks - 10 days after surgery. Samples will be shipped to the participating laboratories OSU Comprehensive Cancer Center CCC Pharmacoanalytical Shared Resource PhASR and Nationwide Childrens Research Institute for assessment of intratumoral drug concentration and assessment of intratumoral disease markers. During surgery, four blood samples will also be obtained and sent to the cooperating laboratory PhASR for determination of drug concentration and molecular analysis. 